NCT04127695 - A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease | Biotech Hunter

Timeline

Start Date

March 3, 2020

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions

Parkinson's Disease

Interventions

DRUG

ABBV-0805

ABBV-0805 administered by IV infusion.

DRUG

Placebo ABBV-0805

Placebo ABBV-0805 administered by IV infusion.

Trial Locations (6)

University of Florida - Archer /ID# 212823, Gainesville

Columbia Univ Medical Center /ID# 212826, New York

Duke University Medical Center /ID# 214435, Durham

Evergreen Neuroscience Institute /ID# 212827, Kirkland

Inland Northwest Research /ID# 212119, Spokane

University of Puerto Rico, Medical Sciences Campus /ID# 215751, Rio Piedras